-54%

est. 2Y upside i

HealthcareAI & MLRoboticsSeries A

Medra is building the first Physical AI Scientist that delivers on the tight integration needed between AI that can reason, and AI that can perform experiments. Their Scientific AI can generate hypotheses, design experiments, and interpret results. Its companion system, Medra’s Physical AI, uses general-purpose robots to autonomously run experiments with the flexibility of a human and the scalability of a machine.

Rank

#838

Sector

Biotechnology, Artificial Intelligence, Robotics

Est. Liquidity

~5Y

Data Quality

Data: Medium

Medra presents a strong upside opportunity driven by its innovative Physical AI Scientist platform and a key partnership with Genentech.

Last updated: March 10, 2026

Bull (30%)+400%

Medra's Genentech partnership expands significantly, leading to multiple large enterprise contracts. The proprietary Physical AI Scientist platform achieves breakthroughs in drug discovery, demonstrating superior speed and cost-efficiency compared to traditional methods. Revenue scales rapidly to $150M+ by 2028, justifying a $1.3B+ valuation (5x current) as a market leader in autonomous drug discovery.

Base (20%)+50%

Medra continues to secure additional biopharma partnerships, but faces intense competition from well-funded rivals like Lila Sciences, limiting market share and pricing power. Growth is steady but not explosive, reaching ~$75M in revenue by 2028 and a $390M valuation (1.5x current), reflecting solid execution but a more crowded market.

Bear (50%)-70%

Development of the autonomous lab proves more costly and complex than anticipated, leading to slower-than-expected customer acquisition and higher burn. Competitors, particularly Lila Sciences, gain significant traction, commoditizing parts of Medra's offering. A down round or challenging exit at ~$78M (0.3x current) results in minimal or no return for common stock holders due to liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

24%

Investors hold $63M in liquidation preferences ahead of common stock, which is 24.23% of the current $260M valuation.

Dilution Risk

high

As a Series A company in a capital-intensive sector, Medra will likely need several more funding rounds, leading to significant future dilution.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Medra's shares at this early stage.

Questions to Ask at the Interview

Strategic questions based on Medra's data — designed to show you've done your homework.

  • 1

    “How is Medra planning to strategically differentiate and compete against heavily funded players like Lila Sciences, especially given their broader ambition to build a 'full scientific superintelligence'?”

  • 2

    “With the plan to build one of the largest autonomous labs in the US, how will Medra balance serving external biopharma partners with potentially developing its own internal drug discovery capabilities, and what is the long-term revenue model for each approach?”

  • 3

    “Given the capital-intensive nature of building physical AI labs and the likelihood of future funding rounds, what is the company's philosophy on managing dilution for early employees, and what is the anticipated timeline for a liquidity event?”

Community

Valuation Sentiment

Our model estimates -54% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.